Literature DB >> 15166270

Inflammatory cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma.

I Esposito1, M Menicagli, N Funel, F Bergmann, U Boggi, F Mosca, G Bevilacqua, D Campani.   

Abstract

BACKGROUND: Inflammatory cells contribute to the growth and spread of human malignancies by producing molecules that enhance tumour invasiveness. AIMS: To characterise the inflammatory infiltrate in pancreatic ductal adenocarcinoma and to analyse its contribution to angiogenesis and its prognostic relevance.
METHODS: Immunohistochemistry was used to identify inflammatory cells and evaluate the expression of proangiogenic and prolymphangiogenic molecules (vascular endothelial growth factor A (VEGF-A), VEGF-C, and basic fibroblast growth factor (bFGF)) by inflammatory and cancer cells in 137 pancreatic cancers. Intratumorous microvessel density (IMD) was assessed using CD34 as an endothelial cell marker.
RESULTS: There were significantly more mast cells and macrophages in pancreatic cancers than in normal pancreas and the number of mast cells directly correlated with the presence of lymph node metastases. However, there was no relation between numbers of infiltrating inflammatory cells and the presence of chronic pancreatitis (CP)-like changes in the parenchyma surrounding the tumour. Double immunostaining revealed that both pancreatic mast cells and macrophages express VEGF-A, VEGF-C, and bFGF. These factors were also expressed in the tumour cells in many cases. The numbers of VEGF-A expressing tumour cells and bFGF expressing tumour and inflammatory cells significantly correlated with IMD. Moreover, tumours with higher IMD had higher numbers of infiltrating mast cells and macrophages.
CONCLUSIONS: Mononuclear inflammatory cells of the non-specific immune response are recruited to pancreatic cancer tissues independent of the presence of CP-like changes, may influence the metastatic capacity of the cancer cells, and may contribute to the development of tumours with high angiogenic activity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15166270      PMCID: PMC1770337          DOI: 10.1136/jcp.2003.014498

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  48 in total

1.  Detection and localization of Mip-3alpha/LARC/Exodus, a macrophage proinflammatory chemokine, and its CCR6 receptor in human pancreatic cancer.

Authors:  J Kleeff; T Kusama; D L Rossi; T Ishiwata; H Maruyama; H Friess; M W Büchler; A Zlotnik; M Korc
Journal:  Int J Cancer       Date:  1999-05-17       Impact factor: 7.396

Review 2.  Molecular mechanisms in chronic pancreatitis.

Authors:  I Esposito; H Friess; M W Büchler
Journal:  Zentralbl Chir       Date:  2001-11       Impact factor: 0.942

Review 3.  Cancer immunoediting: from immunosurveillance to tumor escape.

Authors:  Gavin P Dunn; Allen T Bruce; Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

4.  Macrophage-induced angiogenesis is mediated by tumour necrosis factor-alpha.

Authors:  S J Leibovich; P J Polverini; H M Shepard; D M Wiseman; V Shively; N Nuseir
Journal:  Nature       Date:  1987 Oct 15-21       Impact factor: 49.962

5.  Angiogenesis in pancreatic carcinoma: thymidine phosphorylase expression in stromal cells and intratumoral microvessel density as independent predictors of overall and relapse-free survival.

Authors:  S Fujioka; K Yoshida; S Yanagisawa; M Kawakami; T Aoki; Y Yamazaki
Journal:  Cancer       Date:  2001-10-01       Impact factor: 6.860

6.  The prognostic relevance of angiogenesis and mast cells in squamous cell carcinoma of the oesophagus.

Authors:  G O Elpek; T Gelen; N H Aksoy; A Erdoğan; L Dertsiz; A Demircan; N Keleş
Journal:  J Clin Pathol       Date:  2001-12       Impact factor: 3.411

7.  Overexpression of lymphangiogenic growth factor VEGF-C in human pancreatic cancer.

Authors:  R F Tang; J Itakura; T Aikawa; K Matsuda; H Fujii; M Korc; Y Matsumoto
Journal:  Pancreas       Date:  2001-04       Impact factor: 3.327

8.  The role of mast cell tryptase in neoangiogenesis of premalignant and malignant lesions of the uterine cervix.

Authors:  L Benítez-Bribiesca; A Wong; D Utrera; E Castellanos
Journal:  J Histochem Cytochem       Date:  2001-08       Impact factor: 2.479

9.  Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression.

Authors:  J Itakura; T Ishiwata; H Friess; H Fujii; Y Matsumoto; M W Büchler; M Korc
Journal:  Clin Cancer Res       Date:  1997-08       Impact factor: 12.531

Review 10.  Requirement of macrophages and eosinophils and their cytokines/chemokines for mammary gland development.

Authors:  Valérie Gouon-Evans; Elaine Y Lin; Jeffrey W Pollard
Journal:  Breast Cancer Res       Date:  2002-06-25       Impact factor: 6.466

View more
  103 in total

1.  Aberrant signaling pathways in pancreatic cancer: a two compartment view.

Authors:  Angela L McCleary-Wheeler; Robert McWilliams; Martin E Fernandez-Zapico
Journal:  Mol Carcinog       Date:  2012-01       Impact factor: 4.784

Review 2.  Pancreatic ductal adenocarcinoma: a review of immunologic aspects.

Authors:  Megan B Wachsmann; Laurentiu M Pop; Ellen S Vitetta
Journal:  J Investig Med       Date:  2012-04       Impact factor: 2.895

Review 3.  Ischaemia is linked to inflammation and induction of angiogenesis in pancreatic islets.

Authors:  T Linn; J Schmitz; I Hauck-Schmalenberger; Y Lai; R G Bretzel; H Brandhorst; D Brandhorst
Journal:  Clin Exp Immunol       Date:  2006-05       Impact factor: 4.330

4.  Crosstalk between mast cells and pancreatic cancer cells contributes to pancreatic tumor progression.

Authors:  Matthew J Strouch; Eric C Cheon; Mohammad R Salabat; Seth B Krantz; Elias Gounaris; Laleh G Melstrom; Surabhi Dangi-Garimella; Edward Wang; Hidayatullah G Munshi; Khashayarsha Khazaie; David J Bentrem
Journal:  Clin Cancer Res       Date:  2010-04-06       Impact factor: 12.531

5.  Impact of microvessel density on lymph node metastasis and survival after curative resection of pancreatic cancer.

Authors:  Christoph Benckert; Armin Thelen; Thorsten Cramer; Wilko Weichert; Gereon Gaebelein; Reinhard Gessner; Sven Jonas
Journal:  Surg Today       Date:  2011-11-10       Impact factor: 2.549

Review 6.  Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy.

Authors:  Amedeo Amedei; Elena Niccolai; Domenico Prisco
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

7.  Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization.

Authors:  Selene Nunez-Cruz; Phyllis A Gimotty; Matthew W Guerra; Denise C Connolly; You-Qiang Wu; Robert A DeAngelis; John D Lambris; George Coukos; Nathalie Scholler
Journal:  Neoplasia       Date:  2012-11       Impact factor: 5.715

Review 8.  Obesity, pancreatitis, and pancreatic cancer.

Authors:  Andrew A Gumbs
Journal:  Obes Surg       Date:  2008-06-19       Impact factor: 4.129

Review 9.  Interplay of tumor microenvironment cell types with parenchymal cells in pancreatic cancer development and therapeutic implications.

Authors:  Praveen Guturu; Vijay Shah; Raul Urrutia
Journal:  J Gastrointest Cancer       Date:  2009-06-10

Review 10.  Pancreatic cancer: Update on immunotherapies and algenpantucel-L.

Authors:  Kinsey A McCormick; Andrew L Coveler; Gabriela R Rossi; Nicholas N Vahanian; Charles Link; E Gabriela Chiorean
Journal:  Hum Vaccin Immunother       Date:  2016-03-03       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.